When Every Day Matters – Make Sure You Are Advocating for Yourself

anti-estrogen treatment

Five, seven or ten? No – it’s not a trendy store for juniors… it is a real-life anti-estrogen treatment dilemma facing oncologists and their post-menopausal, ER+, early-stage, breast cancer patients. Standard of care is to take anti-estrogen treatment for at least the first 5 years after diagnosis to help prevent hormone-receptor positive breast cancer recurrences.

VIEW MORE

The world’s best-known breast cancer experts weigh in on issues related to ER+ early stage breast cancer – Part 1

In a consensus report published last week, Endocrine therapy and related issues in hormone receptor‑positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG), the BCTEG addressed four gaps in current guidance for oncologists related to the most common form of breast cancer, estrogen receptor positive (ER+) early stage breast …

VIEW MORE

Restarting Anti-Estrogen Therapy for Breast Cancer

anti-estrogen therapy

Anti-estrogen therapy is an important part of the treatment for patients with early stage estrogen-receptor-positive breast cancer. These treatments can greatly improve a patient’s odds of beating cancer, but they also can come with difficult side effects and toxicities.

VIEW MORE